MiR-130a在上皮性卵巢癌铂类敏感与耐药患者血清中的表达及相关机制研究  

Expression of MiR-130 ain Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance

作　　者：陈岑[1] 王红静[1] 杨凌云[1] 贾西彪[1] 徐盼[1] 陈静[1] 刘亚[1] 

机构地区：[1]四川大学华西第二医院妇产科,成都610041

出　　处：《四川大学学报（医学版）》2016年第1期60-63,共4页Journal of Sichuan University(Medical Sciences)

基　　金：四川省科技厅科技支撑计划项目(No.2012SZ0022)资助

摘　　要：目的分析miR-130a在上皮性卵巢癌铂类敏感与耐药患者血清中的表达情况,探讨其耐药的相关机制。方法选取32例上皮性卵巢癌铂类化疗耐药患者及30例化疗敏感患者,采用实时荧光定量PCR检测受试者血清中miR-130a表达差异,ELISA法检测血清中人第10号染色体缺失的磷酸酶及张力蛋白同源的基因(phosphatase and tensin homolog deleted on chromosome ten,PTEN)、B淋巴细胞瘤-2基因(B-cell lymphoma-2,BCL-2)表达情况。结果耐药组患者血清miR-130a和BCL-2表达均高于敏感组,而PTEN表达低于敏感组(P均<0.05)。且随着组织学分级增加及淋巴转移的发生,耐药组患者血清miR-130a表达量显著升高(P<0.05)。结论 MiR-130a可能通过抑制PTEN激活PI3K/AKT信号通路、上调BCL-2抑制肿瘤细胞凋亡参与上皮性卵巢癌铂类化疗耐药的产生,miR-130a有望成为逆转上皮性卵巢癌化疗耐药的基因治疗新靶点。Objective To determine the expression of miR-130 ain patients with epithelial ovarian cancer and its association with platinum resistance.Methods 32 patients with platinum resistance and 30 patients without platinum resistance were recruited in this study.Real-time PCR was performed to detect the expression of miR-130 a in the serum samples of the patients.ELISA was used to measure the expression level of phosphatase and tensin homolog deleted on chromosome ten（PTEN）and B-cell lymphoma-2（BCL-2）.Results Platinum-resistant patients had significantly higher levels of expression of miR-130 aand BCL-2,and lower level of PTEN than platinumsensitive patients（P〈0.05）.The expression level of miR-130 aincreased with increased severity in histological classification and appearance of lymph node metastasis in the platinum-resistant patients（P〈0.05）.ConclusionMiR-130 amay mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2to inhibit tumor cell apoptosis.MiR-130 amay be a new potential target of gene therapy in platinum-resistant ovarian cancers.

关 键 词：卵巢癌 铂类耐药 miR-130a 机制 

分 类 号：R737.31[医药卫生—肿瘤]